Entinostat plus Pembrolizumab in Patients with Metastatic NSCLC Previously Treated with Anti-PD-(L)1 Therapy.
Matthew D HellmannPasi A JänneMateusz OpyrchalNavid HafezLuis E RaezDmitry I GabrilovichFang WangJane B TrepelMin-Jung LeeAkira YunoSusan BrouwerSerap SankohLei WangDavid TamangEmmett V SchmidtMichael L MeyersSuresh S RamalingamElaine ShumPeter OrdentlichPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)
In anti-PD-(L)1-experienced patients with NSCLC, entinostat plus pembrolizumab did not achieve the primary response rate endpoint but provided a clinically meaningful benefit, with objective response in 9% of patients. No new toxicities, including immune-related adverse events, were seen for either drug. Future studies will continue to evaluate the association of monocyte levels and response.
Keyphrases
- advanced non small cell lung cancer
- small cell lung cancer
- end stage renal disease
- newly diagnosed
- chronic kidney disease
- ejection fraction
- stem cells
- prognostic factors
- endothelial cells
- emergency department
- bone marrow
- epidermal growth factor receptor
- mesenchymal stem cells
- peripheral blood
- cell therapy
- smoking cessation